Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks
Nicholas H. Saadah,
Martin R. Schipperus,
Johanna C. Wiersum-Osselton,
Marian G. van Kraaij,
Camila Caram-Deelder,
Erik A.M. Beckers,
Anja Leyte,
Jan M.M. Rondeel,
Karen M.K. de Vooght,
Floor Weerkamp,
Jaap Jan Zwaginga,
Johanna G. van der Bom
Affiliations
Nicholas H. Saadah
Jon J. van Rood Centre for Clinical Transfusion Research, Sanquin Research, Leiden;Deptartment of Clinical Epidemiology, Leiden University Medical Centre, Leiden;;TRIP, National Hemovigilance & Biovigilance Office, Leiden;
Martin R. Schipperus
TRIP, National Hemovigilance & Biovigilance Office, Leiden;;Haga Teaching Hospital, Department of Haematology, The Hague
Jon J. van Rood Centre for Clinical Transfusion Research, Sanquin Research, Leiden;Deptartment of Clinical Epidemiology, Leiden University Medical Centre, Leiden;
Erik A.M. Beckers
Department of Haematology, Maastricht University Medical Centre, Maastricht
Anja Leyte
Department of Clinical Chemistry, OLVG Location East, Amsterdam
Jan M.M. Rondeel
Department of Clinical Chemistry, Isala Clinics, Zwolle
Karen M.K. de Vooght
Department of Clinical Chemistry, University Medical Centre Utrecht, Utrecht
Floor Weerkamp
Department of Clinical Chemistry, Maasstad Hospital, Rotterdam
Jaap Jan Zwaginga
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Centre, Leiden, the Netherlands
Johanna G. van der Bom
Jon J. van Rood Centre for Clinical Transfusion Research, Sanquin Research, Leiden;Deptartment of Clinical Epidemiology, Leiden University Medical Centre, Leiden;
Plasma transfusion is indicated for replenishment of coagulative proteins to stop or prevent bleeding. In 2014, the Netherlands switched from using ~300mL fresh frozen plasma (FFP) units to using 200mL Omniplasma, a solvent/detergent treated pooled plasma (SD plasma), units. We evaluated the effect of the introduction of SD plasma on clinical plasma use, associated bleeding, and transfusion reaction incidences. Using diagnostic data from six Dutch hospitals, national blood bank data, and national hemovigilance data for 2011 to 2017, we compared the plasma/red blood cell (RBC) units ratio (f) and the mean number of plasma and RBC units transfused for FFP (~300mL) and SD plasma (200mL) for various patient groups, and calculated odds ratios comparing their associated transfusion reaction risks. Analyzing 13,910 transfusion episodes, the difference (Δf = fSD - fFFP) in mean plasma/RBC ratio (f) was negligible (Δfentire_cohort = 0.01 [95% confidence interval (CI): −0.02 - 0.05]; P=0.48). SD plasma was associated with fewer RBC units transfused per episode in gynecological (difference of mean number of units −1.66 [95% CI: −2.72, −0.61]) and aneurysm (−0.97 [−1.59, −0.35]) patients. SD plasma was further associated with fewer anaphylactic reactions than FFP (odds ratio 0.37 [0.18, 0.77; P
